Home/Filings/4/0001104659-15-003029
4//SEC Filing

Radius Health, Inc. 4

Accession 0001104659-15-003029

CIK 0001428522operating

Filed

Jan 15, 7:00 PM ET

Accepted

Jan 16, 9:10 PM ET

Size

22.5 KB

Accession

0001104659-15-003029

Insider Transaction Report

Form 4
Period: 2015-01-16
Transactions
  • Other

    Common Stock Warrant

    2015-01-16121,3960 total(indirect: By Fund)
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (121,396 underlying)
  • Other

    Common Stock

    2015-01-161,794,9830 total
  • Other

    Common Stock Warrant

    2015-01-16249,9320 total
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (249,932 underlying)
  • Other

    Common Stock

    2015-01-16871,8510 total(indirect: By Fund)
Transactions
  • Other

    Common Stock

    2015-01-161,794,9830 total
  • Other

    Common Stock Warrant

    2015-01-16121,3960 total(indirect: By Fund)
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (121,396 underlying)
  • Other

    Common Stock

    2015-01-16871,8510 total(indirect: By Fund)
  • Other

    Common Stock Warrant

    2015-01-16249,9320 total
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (249,932 underlying)
Transactions
  • Other

    Common Stock Warrant

    2015-01-16121,3960 total(indirect: By Fund)
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (121,396 underlying)
  • Other

    Common Stock Warrant

    2015-01-16249,9320 total
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (249,932 underlying)
  • Other

    Common Stock

    2015-01-16871,8510 total(indirect: By Fund)
  • Other

    Common Stock

    2015-01-161,794,9830 total
Transactions
  • Other

    Common Stock

    2015-01-161,794,9830 total
  • Other

    Common Stock Warrant

    2015-01-16121,3960 total(indirect: By Fund)
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (121,396 underlying)
  • Other

    Common Stock Warrant

    2015-01-16249,9320 total
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (249,932 underlying)
  • Other

    Common Stock

    2015-01-16871,8510 total(indirect: By Fund)
Transactions
  • Other

    Common Stock Warrant

    2015-01-16249,9320 total
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (249,932 underlying)
  • Other

    Common Stock

    2015-01-161,794,9830 total
  • Other

    Common Stock

    2015-01-16871,8510 total(indirect: By Fund)
  • Other

    Common Stock Warrant

    2015-01-16121,3960 total(indirect: By Fund)
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (121,396 underlying)
Transactions
  • Other

    Common Stock

    2015-01-16871,8510 total(indirect: By Fund)
  • Other

    Common Stock Warrant

    2015-01-16121,3960 total(indirect: By Fund)
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (121,396 underlying)
  • Other

    Common Stock Warrant

    2015-01-16249,9320 total
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (249,932 underlying)
  • Other

    Common Stock

    2015-01-161,794,9830 total
Transactions
  • Other

    Common Stock Warrant

    2015-01-16249,9320 total
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (249,932 underlying)
  • Other

    Common Stock

    2015-01-161,794,9830 total
  • Other

    Common Stock

    2015-01-16871,8510 total(indirect: By Fund)
  • Other

    Common Stock Warrant

    2015-01-16121,3960 total(indirect: By Fund)
    Exercise: $2.69From: 2014-02-14Exp: 2019-02-14Common Stock (121,396 underlying)
Footnotes (4)
  • [F1]Reflects a liquidating pro rata distribution by F2 Bioscience IV L.P. ("F2 IV") to its limited and general partners.
  • [F2]The reported securities are owned directly by F2 IV. F2 Bioscience IV GP Ltd. ("F2 IV GP") is the General Partner of F2 IV. Katherine Priestley and Globeways Holdings Limited ("Globeways") are members of F2 IV GP. F2 Capital Limited ("F2 Capital") is an investment adviser to F2 IV. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  • [F3]Reflects a liquidating pro rata distribution by F2 Bio Ventures V L.P. ("F2 Bio") to its limited and general partners.
  • [F4]The reported securities are owned directly by F2 Bio. F2 Bio Ventures GP Ltd. is the General Partner of F2 Bio. Globeways is the sole member of F2 Bio Ventures GP Ltd. F2 Capital is an investment adviser to F2 Bio. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Documents

1 file

Issuer

Radius Health, Inc.

CIK 0001428522

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001428522

Filing Metadata

Form type
4
Filed
Jan 15, 7:00 PM ET
Accepted
Jan 16, 9:10 PM ET
Size
22.5 KB